Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Exchanges: DPD2)

Imagin Medical is developing imaging solutions for minimally invasive surgical procedures where endoscopes are used and believes it will radically improve the way physicians detect cancer and view the surgical field. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. The ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com - MORE

 The Company has achieved its initial milestones and has laid the foundation for continued progress and success in 2017:

 •         Completed the development of the i/Blue Imaging System Alpha B Prototype, a patent-protected endoscopic visualization technology for the early detection of cancer. Due to its innovative optical components, the i/Blue is expected to produce images 100 times more sensitive than systems currently available, highlighting the cancer lesions in less than 10 minutes compared to the current market standard of one hour. This will make these procedures more practical, improve outcomes and expand the market.

•         Clinical Research study will begin after the Company receives Internal Review Board Approval from the University of Rochester Medical Center. Dr. Edward Messing, Chair of the Urology Department, will conduct validate the technology using the prototype in humans. The Company anticipates additional clinical studies will be conducted at UC Davis Medical Center, the University of Rochester Medical Center and other institutions.

•         Design for manufacturability is in process by Optel, Inc, a firm uniquely qualified to deliver Imagin’s higher quality imaging technology in a product only 30% the size of the prototype. The i/Blue system will become a mobile device that can be easily moved between different operating rooms and physicians’ offices.

•         First product samples are expected to be available by mid-year, and a final product for commercialization by year end. The product will be highly manufacturable and cost effective, and will become the basic platform for Imagin to expand from bladder cancer to other minimally invasive surgical procedures requiring improved visualization.

•         Imagin believes the i/Blue system will support the new 2016 American Urological Association (AUA) guidelines for bladder cancer detection.

 For further information, contact: Bill Galine, Investor Relations

Telephone: (775) 737-3292  Email: billgaline@gmail.com

About BioTechReporter.net : 

BioTechReporter.net is a subsidiary of Target Publishing Inc, and is a leading publisher of todays market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications, market exposure and investment. 

A complete disclaimer can be viewed HERE

X